Refine Your Search

  • Solutions

  • Therapeutic Areas

  • Resource Type

Optimizing Drug Development Decisions: Looking Back at 2016

Was it just me or did 2016 just seem to fly by? Reflecting on the events of the past year, I stumbled across this quote which seemed appropriate: There are years that ask questions and years that answer. [Zora Neale Hurston, Their Eyes Were Watching God] Our mission at Certara is helping our clients optimize […]

Solution: PK/PD Modeling & Simulation
More Info

Can QSP Save Lives? Lessons from the Bial Trial Debacle

One of the biggest challenges for the pharmaceutical industry is the high rate of drug attrition in Phase 2 clinical trials, which wastes significant amounts of money and time. The major reasons for this attrition are that either candidate drugs do not show efficacy or have unexpected toxicity, in turn implying that we did not fully understand the complexity of the biology the candidate drugs were designed to modulate.

Speaker(s): Neil Benson
Solution: Model-informed Drug Development, Systems Pharmacology
Therapeutic Area: Central Nervous System
More Info

Certara Acquires Quantitative Systems Pharmacology Consultancy, XenologiQ

PRINCETON, NJ – Dec. 1, 2015 – Certara®, the global biosimulation technology-enabled drug development company, today announced that it has acquired XenologiQ, a UK-based quantitative systems pharmacology (QSP) consultancy. “This transaction strengthens Certara’s modeling and simulation capabilities, increases its leadership in mechanistic pharmacology, and supports the company’s precision medicine vision,” said Certara Chief Executive Officer […]

More Info
Learn More LinkedIn Twitter Facebook Email